Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

315 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial.
Song Y, Tilly H, Rai S, Zhang H, Jin J, Goto H, Terui Y, Shin HJ, Kim WS, Cao J, Feng J, Eom HS, Kim TM, Tsai XC, Gau JP, Koh H, Zhang L, Song Y, Yang Y, Li W, Huang H, Ando K, Sharman JP, Sehn LH, Bu L, Wang X, Jiang Y, Hirata J, Lee C, Zhu J, Izutsu K. Song Y, et al. Among authors: terui y. Blood. 2023 Apr 20;141(16):1971-1981. doi: 10.1182/blood.2022017734. Blood. 2023. PMID: 36626583 Free PMC article. Clinical Trial.
Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study.
Kim WS, Fukuhara N, Yoon DH, Yamamoto K, Uchida T, Negoro E, Izutsu K, Terui Y, Nakajima H, Ando K, Suehiro Y, Kang HJ, Ko PS, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Tobinai K. Kim WS, et al. Among authors: terui y. Blood Adv. 2023 Sep 12;7(17):4903-4912. doi: 10.1182/bloodadvances.2022008615. Blood Adv. 2023. PMID: 36661315 Free PMC article. Clinical Trial.
Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Negoro E, Yamauchi T, Fukuhara N, Yamamoto K, Uchida T, Izutsu K, Maruyama D, Terui Y, Nakajima H, Ando K, Suehiro Y, Choi I, Kanemura N, Nakamura N, Yamamoto G, Maeda Y, Shibayama H, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Kim WS, Tobinai K. Negoro E, et al. Among authors: terui y. J Clin Exp Hematop. 2023;63(2):108-120. doi: 10.3960/jslrt.23005. J Clin Exp Hematop. 2023. PMID: 37380467 Free PMC article. Clinical Trial.
Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.
Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, Choi I, Okubo S, Ogawa N, Sakai M, Nishimura Y, Chyla B, Sun Y, Maruyama D. Izutsu K, et al. Among authors: terui y. Int J Hematol. 2023 Oct;118(4):526-528. doi: 10.1007/s12185-023-03646-3. Epub 2023 Aug 15. Int J Hematol. 2023. PMID: 37581752 Free PMC article. No abstract available.
Successful Treatment of Diffuse Large B-cell Lymphoma Involving Multiple Renal and Bone Infiltrations Presenting with Giant Cell Arteritis-like Manifestations.
Yokota K, Morimoto K, Yazawa H, Tsuzuki Wada T, Sakamoto T, Terui Y, Kaneko S, Inoue T, Okada H, Akiyama Y, Mimura T. Yokota K, et al. Among authors: terui y. Intern Med. 2024 Jun 1;63(11):1645-1652. doi: 10.2169/internalmedicine.2377-23. Epub 2023 Nov 13. Intern Med. 2024. PMID: 37952957 Free PMC article.
Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib.
Arakawa Y, Narita Y, Nagane M, Mishima K, Terui Y, Yonezawa H, Asai K, Fukuhara N, Sugiyama K, Shinojima N, Aoi A, Nishikawa R. Arakawa Y, et al. Among authors: terui y. Neurooncol Adv. 2023 Sep 14;5(1):vdad109. doi: 10.1093/noajnl/vdad109. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37744697 Free PMC article.
315 results